Digital Health Innovations
Strategic Digital Health Engagements
Shape the Future of Healthcare with Digital Solutions.
Transform your strategy with The Dedham Group’s Digital Health & Access Innovation Division. With over 20 years of experience, our experts provide unmatched insights and strategies for pharmaceutical manufacturers, digital health innovators, and investors. Utilizing exclusive data and the latest trends, we help you make informed decisions, craft effective go-to-market strategies, and seize digital health opportunities.
Schedule a Meeting
Services for Pharmaceutical Manufacturers
Digital Health Market Shaping:
Uncover digital solution partnerships to advance the clinical standard of care within therapeutic areas, such as implementing digital endpoints, interventions, and enhancing care delivery.
Patient Identification Innovation:
Discover digital health investments or partnerships that drive innovation in patient identification and diagnostics, including disease screening, AI-assisted diagnostics, non-invasive diagnostic modalities, and precision medicine collaborations.
Therapy Access Optimization:
Explore how digital health solutions or partnerships can enhance therapy access among payers and improve clinical perceptions among providers and patients.
AE & Care Management:
Identify digital health solutions that address therapy adverse event profiles or improve care coordination and remote patient monitoring to optimize patient outcomes and support treatment durability.
Services for Digital Manufacturers
Market Opportunity & Commercial Viability:
Determine the most promising therapeutic areas and markets for R&D investment based on factors like market size, customer segmentation, unmet needs, competitive dynamics, and key market trends.
Product & Feature Ideation & Recommendations:
Recommend product features based on customer needs, expected adoption and reimbursement dynamics, solution stickiness, and anticipated clinical impact.
Vendor Due Diligence & Capabilities Benchmarking:
Assess competitor stakeholders within therapeutic areas, evaluating product differentiation in terms of customer customization, guidance, and impact on user experience and clinical outcomes.
Go-to-Market and BD&L Strategy:
Develop reimbursement and demand-generation strategies and identify potential business development or licensing opportunities with stakeholders such as pharmaceutical companies.
We Provide:
Unparalleled Expertise
Our experts add substantial value by covering a wide range of services, including opportunity assessments, go-to-market strategies, deep therapeutic needs assessments, and product and feature development.
Established Panel Network
In-depth Digital Health Experience
Case Studies:
Additional Resources:
The FDA’s PDURS Guidance: What Manufacturers Need to Know
In September 2023, the FDA released a new guidance document titled Regulatory Considerations for Prescription Drug Use-Related Software (PDURS). This guidance outlines how the FDA intends to apply its drug labeling authorities to software outputs associated with prescription drugs or drug-device combination products. It also opens several opportunities for brand differentiation and commercial success. Here’s what pharma manufacturers need to know about this guidance and how to prepare.
How Virtual Care and Digital Pharmacies are Transforming the Healthcare Experience
If you’ve tuned into the news within the past few months, you’ll have seen Mark Cuban discussing his plans to lower pharmacy drug costs for patients. His namesake pharmacy, Mark Cuban Cost Plus Drug Company (MCCPDC), aims to manufacture and deliver low-cost therapies at a flat, transparent 15% markup plus a pharmacist fee. From digital pharmacies to other methods of virtual care, the healthcare experience is undergoing a rapid transformation. While care delivery models are still evolving, they bring new opportunities for pharma to increase value to patients.
